News Posts List
MDACC 2018: Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesnât?
11/12/2018
Our 2017 YIA winner Pavlos Msaouel is doing great work in kidney cancer research. In this article, he explains chemotherapy vs. targeted therapies.
MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
11/12/2018
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.
MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
11/12/2018
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.
MDACC 2018: Debate: What is the Best Salvage Therapy After Failure of Immune Checkpoint Inhibition?
11/12/2018
Dr. Msaouel discusses the best treatment options after failure of immune checkpoint inhibition.
Personalized Immunotherapy Combinations on Horizon
11/09/2018
Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment, according to a presentation by Jason Luke, MD, at the 36th Annual CFS.
Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study
11/09/2018
Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.
Sunitinib Alone or after Nephrectomy in Renal Cancer
11/09/2018
In the CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) trial, Méjean et al. (Aug. 2 issue)1 determine the noninferiority of sunitinib alone, as compared with nephrectomy followed by sunitinib, on the basis of the observation that the 95% confidence interval for the hazard ratio of death did not exceed 1.20 (the noninferiority margin for the trial).
Systemic Therapy Options for Renal Cell Carcinoma
11/09/2018
Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space.
Front-Line Combo Found Superior for Advanced RCC
11/08/2018
Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC), according to study findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany.
Distress Levels High Among Patients With Common Form of Kidney Cancer
11/08/2018
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.
News Feed